Agios Pharmaceuticals(NASDAQ) AGIO

Market Cap$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-0%
5 Year-28%
1 Year-23%
1 Month-6%
Premium Feature
Moneyball Superscore
67/100
$31.82
+1.82%
+0.57Today
Agios Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 31.252026-10-05
Agios Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.49%USD 33.422026-09-28
1 month-5.59%USD 33.102026-09-04
3 month-28.99%USD 44.012026-07-07
Year to date+14.81%USD 27.222025-12-31
1 year-22.84%USD 40.502025-10-03
3 year+30.21%USD 24.002023-10-06
5 year-27.85%USD 43.312021-10-06
Since inception-0.1%USD 31.282013-07-24

Agios Pharmaceuticals Financials at a Glance

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$98.34

Net Income (TTM)

-$411.29

EPS (TTM)

-$7.01

P/E Ratio

-4.46

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$31.82

Volume

377,889.85

Open

$31.49

Previous Close

$31.25

Daily Range

$30.79 - $31.98

52-Week Range

$22.24 - $46.00

Estimated Earnings Date

N/A

AGIO: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Industry

Biotechnology

Employees

540

CEO

Brian M. Goff, MBA

AGIO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-34.34%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-22.42%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.70M

Volume

377.89K

Avg. Volume

1.07M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Agios Pharmaceuticals Performance Analysis

Agios Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,240,000N/A
20232023-12-31USD 26,823,00088.4%
20242024-12-31USD 36,498,00036.1%
20252025-12-31USD 54,028,00048.0%
Agios Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.23-33.5%
20232023-12-31USD -6.3349.5%
20242024-12-31USD 11.64N/A
20252025-12-31USD -7.12N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$44.75

+3.6%

Gross Profit

$40.40

+4.3%

Gross Margin

90.29%

+1.2%

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.09

N/A

Employees

540

N/A

Net Income

-$100.70

+0.9%

EBITDA

-$109.20

+0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$130.82

+0.9%

Total Debt

$31.17

+0.6%

Accounts Receivable

$20.11

+4.0%

Inventory

$30.15

+1.0%

Long Term Debt

$11.95

+0.4%

Short Term Debt

$19.23

+1.1%

Return on Assets

-31.89%

-0.6%

Return on Invested Capital

-15.51%

+0.7%

Free Cash Flow

-$58.52

+0.8%

Operating Cash Flow

-$57.31

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About AGIO

What is the current price of Agios Pharmaceuticals?

Agios Pharmaceuticals is trading at $31.71 per share.

What is the 52-week range for Agios Pharmaceuticals?

Over the past 52 weeks, Agios Pharmaceuticals has traded between $22.24 and $46.00.

How much debt does Agios Pharmaceuticals have?

As of the most recent reporting period, Agios Pharmaceuticals reported total debt of $31.17M.

How much cash does Agios Pharmaceuticals have on hand?

Agios Pharmaceuticals reported $99.65M in cash and cash equivalents in its most recent financial results.

What is Agios Pharmaceuticals’s dividend yield?

Agios Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.